COST effectivenessQUALITY-adjusted life yearsOVERALL survivalBackground: A recent phase III clinical trial (NCT03981796) evaluated the efficacy and safety of dostarlimab combined with carboplatin-paclitaxel (DOSCP) compared to placebo combined with carboplatin-paclitaxel (PLB-CP) as...
Nonetheless, the current data would suggest the combination of carboplatin/paclitaxel with dostarlimab makes sense for these patients. When we think about sequencing for patients, using carboplatin/paclitaxel with a checkpoint inhibitor seems to be the appropriate frontline treatment ...
ENGOT-EN6/GOG-3031/NSGO-RUBY: A phase 3, randomized, double-blind, multicenter study of dostarlimab plus carboplatin-paclitaxel versus placebo plus carbopl... L Hanker,MR Mirza,RL Coleman,... - 《Oncology Research & Treatment》 被引量: 0发表: 2020年 ENGOT-EN6/GOG-3031/NSGO-RUBY: A...
Budget impact of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a third-party US payer perspectiveSolomon J. LubingaLydia WalderMark BurtonQin Shen